SAREPTA THERAPEUTICS, INC. Business Combination, Contingent Consideration, Liability
SAREPTA THERAPEUTICS, INC. (SRPT) had Business Combination, Contingent Consideration, Liability of $47.40 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2026-08-05
- 2025-12-31: Business Combination, Contingent Consideration, Liability $47.40M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability $36.30M.
- 2025-06-30: Business Combination, Contingent Consideration, Liability $47.40M.
- 2025-03-31: Business Combination, Contingent Consideration, Liability $47.40M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2025-12-31 | $47.40M 10-K · filed 2026-03-02 |
| 2025-09-30 | $36.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $47.40M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $47.40M 10-Q · filed 2025-05-06 |
| 2025-01-01 | $47.40M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $47.40M 10-K · filed 2026-03-02 |
| 2024-09-30 | $47.40M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $48.20M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $48.20M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $38.10M 10-K · filed 2025-02-28 |
| 2023-09-30 | $38.10M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $36.10M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $36.90M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $36.90M 10-K · filed 2024-02-28 |
| 2022-09-30 | $36.90M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $43.60M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $43.60M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $43.60M 10-K · filed 2023-02-28 |
| 2021-09-30 | $43.60M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $50.80M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $50.80M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $50.80M 10-K · filed 2022-03-01 |
| 2020-09-30 | $50.50M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.20M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $5.20M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.20M 10-K · filed 2021-03-01 |
| 2019-09-30 | $5.20M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $5.20M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |